Ajanta Pharma Limited Stock

Equities

AJANTPHARM

INE031B01049

Pharmaceuticals

Delayed NSE India S.E. 06:02:23 2024-04-25 am EDT 5-day change 1st Jan Change
2,140 INR +0.29% Intraday chart for Ajanta Pharma Limited +2.94% +2.70%
Sales 2024 * 42.01B 504M Sales 2025 * 47.09B 566M Capitalization 269B 3.23B
Net income 2024 * 8.08B 97.02M Net income 2025 * 9.5B 114M EV / Sales 2024 * 6.21 x
Net cash position 2024 * 7.97B 95.72M Net cash position 2025 * 13.8B 166M EV / Sales 2025 * 5.41 x
P/E ratio 2024 *
33.6 x
P/E ratio 2025 *
28.4 x
Employees 7,713
Yield 2024 *
0.95%
Yield 2025 *
0.78%
Free-Float 50.31%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.29%
1 week+2.94%
Current month-4.07%
1 month-3.74%
3 months-2.06%
6 months+24.52%
Current year+2.70%
More quotes
1 week
2 069.15
Extreme 2069.15
2 189.25
1 month
2 051.60
Extreme 2051.6
2 317.65
Current year
1 998.35
Extreme 1998.35
2 353.95
1 year
1 246.75
Extreme 1246.75
2 353.95
3 years
1 061.77
Extreme 1061.7667
2 353.95
5 years
550.00
Extreme 550
2 353.95
10 years
259.52
Extreme 259.52
2 353.95
More quotes
Managers TitleAgeSince
Chief Executive Officer 48 98-12-31
Chief Executive Officer 52 95-12-31
Director of Finance/CFO 59 98-04-22
Members of the board TitleAgeSince
Chief Executive Officer 52 95-12-31
Chairman 77 79-12-30
Director/Board Member 78 08-10-19
More insiders
Date Price Change Volume
24-04-25 2,140 +0.29% 35 470
24-04-24 2,134 +0.16% 69,788
24-04-23 2,130 +1.86% 98,235
24-04-22 2,091 +0.29% 138,405
24-04-19 2,085 +0.32% 34,465

Delayed Quote NSE India S.E., April 25, 2024 at 06:02 am EDT

More quotes
Ajanta Pharma Limited is an India-based specialty pharmaceutical company. The Company provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. The Company is engaged in the manufacturing and sale of branded generic and generic pharmaceutical products. It has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its branded generics business is spread across India, the rest of Asia, and Africa. Its business also consists of two verticals: United States generics and institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). The Company's cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
2,134 INR
Average target price
2,271 INR
Spread / Average Target
+6.44%
Consensus
  1. Stock Market
  2. Equities
  3. AJANTPHARM Stock